[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522974":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":39,"centralContacts":47,"locations":56,"responsibleParty":88,"collaborators":90,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":10,"studyType":106,"phases":10,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","OTHER",[8,14,18,22,26,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Group Anti-IL23p19",null,"Patients treated with anti-IL23p19 (risankizumab, guselkumab, mirikizumab, brazikumab)",[13],"Other: Non-interventional",{"label":15,"type":10,"description":16,"interventionNames":17},"Group Jak inhibitors","Patient treated with Jak inhibitors (tofacitinib, upadacitinib, filgotinib)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group S1P Modulators","Patient treated with S1P modulators (ozanimod, etrasimod)",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Group Anti TNF","Patient treated with anti-TNF (infliximab, adalimumab, golimumab) (with a maximal proportion of 25% as 1st first line biologic after conventional treatment (aminosalicylates, corticosteroids, thiopurines, methotrexate))",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Group Anti integrins","Patient treated with anti-integrins (vedolizumab)",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Group Anti IL12\u002F23","Patient treated with anti-IL12\u002F23 (ustekinumab)",[13],[35],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"Non-interventional","This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.",[31,23,27,9,15,19],[40,44],{"name":41,"affiliation":42,"role":43},"Julien Kirchgesner","Hôpital Saint Antoine - APHP","PRINCIPAL_INVESTIGATOR",{"name":45,"affiliation":46,"role":43},"Mathurin Fumery","CHU Amiens-Picardie",[48,53],{"name":49,"role":50,"phone":51,"phoneExt":10,"email":52},"Marie Coisnon","CONTACT","09 72 57 61 60","mcoisnon@getaid.org",{"name":54,"role":50,"phone":51,"phoneExt":10,"email":55},"Charlotte Mailhat","cmailhat@getaid.org",[57,75],{"facility":58,"status":59,"city":60,"state":10,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"CHU Amiens Picardie","RECRUITING","Amiens","80000","France","FR",{"type":65,"coordinates":66},"Point",[67,68],2.3,49.9,{"lat":68,"lon":67},[71,74],{"name":72,"role":50,"phone":10,"phoneExt":10,"email":73},"Mathurin FUMERY, PHD","Fumery.Mathurin@chu-amiens.fr",{"name":72,"role":43,"phone":10,"phoneExt":10,"email":10},{"facility":76,"status":59,"city":77,"state":10,"zip":78,"country":62,"countryCode":63,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"APHP Hôpital Saint Antoine","Paris","75012",{"type":65,"coordinates":80},[81,82],2.3488,48.85341,{"lat":82,"lon":81},[85,87],{"name":41,"role":50,"phone":10,"phoneExt":10,"email":86},"julien.kirchgesner@aphp.fr",{"name":41,"role":43,"phone":10,"phoneExt":10,"email":10},{"type":89,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[91],{"name":92,"class":6},"Sanoia","100522974","ibd-cancer-and-serious-infections-in-france-i-care-2-100522974",false,"NCT06089590","Ibd CAncer and seRious Infections in France (I-CARE 2)","I-CARE 2","Inclusion Criteria:\n\n* Patient with an established diagnosis of Crohn's disease, ulcerative colitis or IBD unclassified based on usual radiological, endoscopic or histological criteria.\n* Patient aged 18 and older accepting to sign the informed participating consent form, stating that he accepts to provide personal details (mobile and home phone number, e-mail address), to complete the e-PRO as required and to be contacted by a Study Coordinator and his gastroenterologist for the purpose of the study during the entire study period and during follow up if required.\n\nExclusion Criteria:\n\n* Patient unable to sign the informed consent form\n* Patient with no regular access to internet\n* Patient refusing to sign the informed consent form\n* Patient enrolled in a Randomized Clinical Trial (If the investigational product received was blinded, and if the treatment is unknown at time of enrolment in I-CARE 2)","ALL","18 Years","75 Years",{"count":104,"type":105},6000,"ESTIMATED","OBSERVATIONAL","This is a French prospective longitudinal observational multicentre cohort study.\n\nPrimary objective : to assess prospectively the presence and the extent of safety concerns (cancer, serious infections, arterial and venous thrombotic events) in patients with CD and UC and treated with JAKi, anti-IL23p19, and S1p modulators.",[109,110,111],"IBD","Ulcerative Colitis","Crohn Disease",[113,114],"UC","CD","2025-03-12",{"date":117,"type":118},"2025-03-14","ACTUAL",{"date":120,"type":118},"2024-01-25",{"date":122,"type":105},"2031-03-01",{"name":5,"class":6},2]